Plain-English translation of NCT04373473 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new oral medication called , which contains beneficial bacteria collected from healthy donors and processed into capsules. The study is designed for adults whose ulcerative colitis is currently under control (in remission) and who have had flare-ups in the past year. Researchers want to see whether taking this medication can help prevent the disease from coming back, compared to a placebo (a capsule that looks identical but contains no bacteria).
Ulcerative colitis often comes back even when patients are doing well, which can be painful and disrupt daily life. This medication is based on the idea that restoring healthy bacteria in the gut might help keep the disease quiet and prevent future flare-ups.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the medication capsules or placebo capsules and take them as instructed while continuing your regular ulcerative colitis treatment. The study involves regular clinic visits where researchers will check how you're doing, collect samples to study your gut bacteria, and monitor for any side effects. The study will track whether you experience any disease flare-ups and compare outcomes between those taking the medication and those taking placebo.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States